Compare RNGR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNGR | FDMT |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | 196 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.7M | 449.6M |
| IPO Year | 2017 | 2019 |
| Metric | RNGR | FDMT |
|---|---|---|
| Price | $16.28 | $8.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $20.00 | ★ $31.71 |
| AVG Volume (30 Days) | 282.0K | ★ 580.4K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.81% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $23.86 | N/A |
| Revenue Next Year | $4.37 | $70.28 |
| P/E Ratio | $136.00 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $10.56 | $3.37 |
| 52 Week High | $18.82 | $12.34 |
| Indicator | RNGR | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.33 | 40.74 |
| Support Level | $15.62 | $8.45 |
| Resistance Level | $17.94 | $8.80 |
| Average True Range (ATR) | 0.52 | 0.66 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 36.80 | 17.36 |
Ranger Energy Services Inc offers high specification mobile rig well services, cased hole wireline services, and ancillary services in the U.S. oil and gas industry. Its services facilitate operations throughout the lifecycle of a well, including the completion, production, maintenance, intervention, workover, and abandonment phases. The company's reportable segments are: High Specification Rigs, Wireline Services, Processing Solutions and Ancillary Services. Maximum revenue is generated from the High Specification Rigs segment, which offers high specification well service rigs and complementary equipment and services to facilitate operations throughout the lifecycle of a well. The high specification rig services consist of well completion support, workovers, and well maintenance services.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).